beyond spring pharma stock

Saturday, April 16, 2022 Edit

5 2017 at 954 am. The live webcast can be accessed here or by visiting the investors section of the BeyondSpring website NEW YORK Apr.

Stock Overview Beyondspring

BeyondSpring is a global clinical-stage bio-pharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with the University of Washington in de novo drug discovery using a.

. The average twelve-month price target for BeyondSpring is 3000 with a high price target of 6500 and a low price target of 500. 14 2022 BeyondSpring Inc. The stock soared nearly 150.

BYSI a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs today announced that it has filed its annual report on Form 20-F for the fiscal. Shares of BeyondSpring BYSI 270 soared on Wednesday after the pharmaceutical company released promising clinical trial results for its investigational lung cancer treatment. BYSI stock are taking off on Wednesday following an important update regarding the firms lung cancer treatment.

Biotechs industry in the US expected to see average net income decline 100 next year. Quickest stock price recoveries post dividend payment. BYSI lost -193 per share in the over the last 12 months.

Revenue forecast of US9127k unchanged since last update. This trading strategy invovles purchasing a stock just before the ex-dividend date in order to collect the dividend and then selling after the stock price has recovered. By the close of.

In China we own a 5797 interest in our Chinese subsidiary Dalian Wanchunbulin Pharmaceuticals Ltd. The consensus outlook for 2021 has been updated. Consensus price target down from US6483 to US2950.

Company to host call today April 14 2022 at 800 am ET Conference call can be accessed by dialing 877-451-6152 US. Is a global biopharmaceutical company that is focused on developing immuno-oncology cancer therapies. 102 rows Discover historical prices for BYSI stock on Yahoo Finance.

BeyondSprings stock was trading at 1135 on March 11th 2020 when Coronavirus reached pandemic status according to the World Health Organization WHO. Shares of BeyondSpring NASDAQ. BeyondSpring is a global clinical-stage bio-pharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal.

Tap the sections below to expand or download the full pipeline chart. ET by Tomi Kilgore. Is a global biopharmaceutical company that is focused on developing immuno-oncology cancer therapies.

The Companyâs lead product Plinabulin which is being studied as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer NSCLC. According to the issued ratings of 6 analysts in the last year the consensus rating for BeyondSpring stock is Hold based on the current 1 sell rating 3 hold ratings and 2 buy ratings for BYSI. BYSI is lower by -408 from the previous closing price of 2291 on volume of 257861 shares.

Beyondspring Inc BYSI stock has fallen -1779 while the SP 500 is lower by -122 as of 940 AM on Monday Sep 20. 1 We own global rights to plinabulin in all countries except China. Any stock with a beta of greater than one is considered more volatile than the market while those with a beta below one are either less volatile or.

1 to 50 Employees. Shares of BeyondSpring BYSI -633 a clinical-stage biotech company have been surging this week in response to a lucrative new partnership with Jiangsu Hengrui Pharmaceuticals. Analyst Sees Little Trouble in Big China.

Global pharmaceutical company BeyondSpring announced positive findings in a late-stage trial of a drug combo to treat second- and third-line nonsmall cell lung cancer. The Closing Price Days High Days Low and Days Volume have been adjusted to account for any stock splits andor dividends which may have occurred for this security since the date shown above. Headquartered in New York BeyondSpring Inc.

The Companyâs lead product Plinabulin which is being studied as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer NSCLC. And Canada or 1-201-389-0879 InternationalThe passcode is 13728822. View which stocks have been most impacted by COVID-19.

Wanchunbulin which owns a 100 interest in plinabulin. View daily weekly or monthly format back to when BeyondSpring Inc. BeyondSpring started at buy with 56 stock price target at Seaport Global.

S hares of BeyondSpring BYSI stock exploded 19 higher in Thursday trading after the NYC-based cancer researcher announced that it has. 18250 305 1700 Allstar Health Brands Inc 060 000 0000 Alseres. The Plinabulin product is a marine-derived small-molecule.

Beyond spring pharma stock Monday February 21 2022 Edit View daily weekly or monthly format back to when BeyondSpring Inc. The Company or BeyondSpring Nasdaq. The pharmaceutical company announced that its.

2021 expected loss increased from -US165 to -US201 per share. NEW YORK April 14 2022 BeyondSpring Inc. Since then BYSI stock has decreased by 804 and is now trading at 222.

Over the past year the SP 500 is higher by 3346 while BYSI is up 3400. The Actual Price is not adjusted for splits or dividends.

Bysi Beyondspring Inc Stock Overview U S Nasdaq Barron S